Whole‐genome sequencing of 1,083 <scp>HPV45</scp> cases and controls identifies genetic variants associated with glandular cervical lesions
Human papillomavirus type 45 (HPV45) causes ~6% of all cervical cancers and an even greater proportion of adenocarcinomas, the latter of which are challenging to detect using current cervical cancer screening. Little is known about how HPV45 genetic variation is related to the risk of cervical precancer/cancer. To investigate this, we whole-genome sequenced a total of 1,083 HPV45-positive samples from two large studies. We evaluated associations of HPV45 genetic variation (sublineages, subclades, and SNPs) with histology-specific precancer/cancer risk using logistic regression and evaluated risk modification by self-reported race/ethnicity. Compared to the common A1 sublineage, A2 and B1 were associated with increased precancer/cancer (A2, OR = 3.9, 95% CI = 1.9-8.5; B1, OR = 2.7, 95% CI = 1.3-5.8; B2, OR = 3.3, 95% CI = 1.6-7.3), and most strongly with the glandular precancers/cancers (AIS/ADC; A2, OR = 6.9, 95% CI = 1.0-184; B1, OR = 6.2, 95% CI = 1.1-159). The A2 sublineage was most prevalent in women in East Asia and women who self-reported as Asian/Pacific Islander (PI) in the U.S.; East Asian and Asian/PI women had the greatest precancer/cancer risk associated with A2 infections (OR = 5.8, 95% CI = 1.3-37.4) compared to all other sublineages among these women. We further evaluated precancer/cancer risk associations for 262 individual HPV45 SNPs and identified four SNPs significantly associated with only glandular precancers/cancers after correction for multiple tests (ORs ranged 7.8-20.7). One of these SNPs was a nonsynonymous variant in both overlapping viral E2/E4 ORFs. In summary, we show that HPV45 genetic variation influences the risk of precancer/cancer, specifically glandular precancer/cancer. Further studies of these genetic variants may improve our understanding of glandular lesions.
Authors
- Chase W. Nelson (ORCID: https://orcid.org/0000-0001-6287-1598)
- Thomas Lorey (ORCID: https://orcid.org/0000-0002-9075-1515)
- Robert David Burk (ORCID: https://orcid.org/0000-0002-8376-8458)
- Lisa Mirabello (ORCID: https://orcid.org/0000-0001-8485-0106)
- Elizabeth Suh‐Burgmann (ORCID: https://orcid.org/0000-0003-4732-1453)
- Sambit Kumar Mishra (ORCID: https://orcid.org/0000-0001-8319-0599)
- Michael Dean (ORCID: https://orcid.org/0000-0003-2234-0631)
- Nicolas Wentzensen (ORCID: https://orcid.org/0000-0003-1251-0836)
- Zigui Chen (ORCID: https://orcid.org/0000-0002-8577-1298)
- Laurie Burdett
- Gary M. Clifford (ORCID: https://orcid.org/0000-0001-7534-333X)
- Philip E. Castle (ORCID: https://orcid.org/0000-0003-1082-6554)
- Meredith Yeager (ORCID: https://orcid.org/0000-0003-3871-2225)
- Mark Schiffman
- A. Koestler (ORCID: https://orcid.org/0009-0002-4983-3997)
Institutions
- Albert Einstein College of Medicine (US)
- Kaiser Permanente (US)
- Chinese University of Hong Kong (HK)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Centre international de recherche sur le cancer (FR)
- Division of Cancer Epidemiology and Genetics
- Hood College (US)
Publication Details
- Journal
- International Journal of Cancer
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1002/ijc.35464
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Albert Einstein Cancer Center
- Institut National Du Cancer
- National Institutes of Health
- National Cancer Institute
- Division of Cancer Epidemiology and Genetics, National Cancer Institute